


**PRODUCT: H3B-6527**

**ALTERNATE NAMES:** H3B 6527; H3B6527; N-{2-[(6-[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methylamino)-4-pyrimidinyl)amino]-5-(4-ethyl-1-piperazinyl)phenyl}acrylamide; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; H3 Biomedicine

**CATALOG#:** B1647-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>29</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>4</sub>

**MOLECULAR WEIGHT:** 629.54

**CAS NUMBER:** 1702259-66-2

**APPEARANCE:** Solid powder

**SOLUBILITY:** DMSO

**PURITY:** >98%

**STORAGE:** Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

**DESCRIPTION:** H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- AZD-4547 (Cat. No. 9403-5, 25)
- BIBF1120 (Cat. No. 2167-5, 25)
- BLU9931 (Cat. No. 9639-5, 25)
- NVP-BGJ398 (Cat. No. 2855-5, 25)
- PD173074 (Cat. No. 1675-1)
- Ponatinib (Cat. No. 2172-10, 50)
- SU-5402 (Cat. No. 1645-05, 1)
- EZSolution™ SU-5402 (Cat. No. 2017-500)
- XL-228 (Cat. No. 2632-1, 5)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*